The whole group in one pane — KPIs, smart alerts, the exhibits (segments, geographies, lines, debt walk, EV bridge), the plant heatmap, and what's on track. Every figure live off the governed dataset, reconciling to ₹15,401 Cr.
Revenue ₹15,401 Cr (▲2.4%), EBITDA ₹1,984 Cr at 12.8% and PAT back to +₹317 Cr (from the −₹691 Cr FY24 trough) — but net debt / EBITDA rose to 4.35x through the ₹2,044 Cr capex cycle. Convert the commissioned assets into FY27 volume, lift value-added mix 33% → 40%, and sweep cash to debt — that sequence is the re-rating.
6 of 8 headline metrics improving vs prior · still off target: Revenue from Operations ₹15,401 Cr vs ₹16,500 Cr, EBITDA (Reported) ₹1,984 Cr vs ₹2,400 Cr, EBITDA Margin (Reported) 12.8% vs 15.0%
Leverage rose 3.73x → 4.35x (peak 4.52x in Q3) as ₹2,044 Cr of capex went in; headroom to the modeled 5.5x ceiling is ~1.15x. OCF ₹992 Cr vs that capex leaves FCF negative by design this year — the FY27 sweep has to show up in prints.
Egypt aseptic (12 bn packs, USD 126 mn) is near commissioning, Sanand is live at 12 bn, Mexico WPP is in validation and Dharwad BOPP lands FY28 — commissioned assets are the whole deleverage plan's engine.
Shift mix to Alox / high-barrier / PCR and push chips third-party volume; hold share, don't chase price.
Packaging Films ₹9,093 Cr (−3.9% YoY) on the ~260 KT India BOPET glut; India films utilization 72.3%.
Natural-hedge via exports, review CIS repatriation quarterly, disclose devaluation sensitivity (FY25 took ₹178 Cr exceptional).
USD/INR averaged 85.4 (Q1) → 91.7 (Q4), closing 94.65; Russia/CIS plant (48 kTPA) operating; West Asia conflict freight risk.
Automatically detected and persona-routed — click any alert to open the 360 that owns it and act.
Consolidated, all segments (₹ Cr) · ₹15,401 Cr revenue · 12.8% reported margin · Q4 exit 15.3% (14-quarter high)
Packaging Films (incl. PET chips) · Flexible Packaging, Aseptic & Holography · Chemicals & Inks · Engineering & Cylinders — Σ ₹15,401 Cr
India 47.0% — over half the group is overseas. Click into Org Roll-up 360 to drill geography → line → plant
| Region | Sites | Revenue | Share | Status |
|---|---|---|---|---|
| India | 6 | ₹7,239 Cr | 47.0% | Watch |
| Americas | 2 | ₹2,818 Cr | 18.3% | On track |
| Europe & CIS | 3 | ₹2,649 Cr | 17.2% | On track |
| Middle East & Africa | 3 | ₹2,249 Cr | 14.6% | On track |
| Rest of Asia & Others | 1 | ₹446 Cr | 2.9% | On track |
Σ line-level EBITDA contribution ≈ ₹2,061 Cr (overlapping lenses — lines cross the 4 segments; not additive to reported ₹1,984 Cr)
Green = integrated / core · amber = still scaling (Asepto, PCR, specialty, chemicals, engineering). Businesses & Brands 360 →
Leverage ROSE through the capex cycle: 3.73x → 3.90 → 4.32 → 4.52 (peak) → 4.35x vs the modeled 5.5x ceiling — headroom ~1.15x. FY27 volume-led deleverage is the plan, not the achievement.
Net debt ₹8,622 Cr (gross ₹9,853 − cash ₹1,231) · interest ₹777 Cr, cover ~2.55x. Deleverage & Re-rating →
EV ₹12,038 Cr − net debt ₹8,622 Cr = market cap ₹3,416 Cr (~6.1x EBITDA · 0.22x sales · 0.42x book) — a deep-value cyclical, not an FMCG multiple.
Promoters 44.58% (pledge nil) ≈ ₹1,523 Cr → public & institutional float ≈ ₹1,893 Cr. Cycle recovery + deleverage + Asepto = the equity torque.
Board-approved targets across the four pillars; current values auto-calculated from live data
| Objective | KPI | Current | Target | Progress | Status |
|---|---|---|---|---|---|
| Lift Value-Added & Converting mix of revenue | Value-added mix | 33% | 40% | 83% | On track |
| Grow specialty / high-barrier share of films (Alox, F-TPM, PCR) | Specialty share of films | 28% | 35% | 80% | On track |
| Expand EBITDA margin toward 15% (Q4 exit was 15.3%) | EBITDA margin | 12.8% | 15% | 85% | Behind |
| Scale aseptic packs sold | Packs sold | 7.97bn | 12bn | 66% | On track |
| Commission Egypt 12 bn-pack greenfield (capacity → 24 bn) | Project completion | 76% | 100% | 76% | On track |
| Scale recycled output toward the 100,000 MT goal | Recycled volume | 30000MT | 100000MT | 30% | On track |
| Ramp Noida rPET (36 kTPA) & MLP (3.6 kTPA) plant | Commissioning | 92% | 100% | 92% | On track |
| Reduce net debt / EBITDA off the 4.35× peak zone | Net debt / EBITDA | 4.35x | 3x | 69% | Behind |
| Shorten DSO (working-capital release) | DSO | 92d | 75d | 82% | Behind |
| Moderate capex as the cycle completes (FY26 ₹2,044 Cr) | Capex | 2044₹Cr | 1400₹Cr | 68% | On track |
Each dot is a plant or unit — 6 India sites + 8 overseas films plants + the export desk. Colour = operational health (green = healthy · amber = watch · red = at risk). Hover for detail; open Plants & Network 360 to act on one.
The four pillars — Value-Added & Specialty Mix · Aseptic (Asepto) Scale-Up · Circularity & Recycling Leadership · Deleverage Through the Cycle — board targets vs live current.
The team's live queue — assign, snooze, resolve.
Action items are managed in Today — your role-filtered decision queue, each with an owner and an action that persists to the audit trail.